Towa Pharmaceutical saw the highest growth of 0.77% in patent filings and 1.32% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and grants by 0.24%. GlobalData’s DataBook provides a comprehensive analysis of Towa Pharmaceutical‘s patent filings and grants. Buy the databook here.
Towa Pharmaceutical has been focused on protecting inventions in South Korea(KR) with nine publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings with nearly 56% of filings. The South Korea(KR), World Intellectual Property Organization(WIPO), United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where Towa Pharmaceutical is filings its patents. Among the top granted patent authorities, Towa Pharmaceutical has 67% of its grants in United States(US), 22% in Portugal(PT) and 11% in European Patent Office(EPO).
ASE Technology could be the strongest competitor for Towa Pharmaceutical
Assembly related patents lead Towa Pharmaceutical portfolio followed by electrical products, and filter tips
Towa Pharmaceutical has highest number of patents in assembly followed by electrical products, filter tips, mobiles, hand-helds, pdas, smartphones, and assembly & testing. For assembly, nearly 17% of patents were filed and 15% of patents were granted in Q2 2024.
For comprehensive analysis of Towa Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.